Nobuaki Matsubara

机构：Chiba Cancer Center, National Cancer Center Hospital East · ORCID：0000-0002-9203-4245

发表论文 481 篇 · 总被引 13228 次 · h-index 41

代表论文

• PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer (2026 · New England Journal of Medicine · 被引 7)
• TALAPRO-3: Talazoparib (TALA) + enzalutamide (ENZA) compared with placebo (PBO) + ENZA for the treatment of patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) harboring homologous recombination repair (HRR) gene alterations. (2026 · Journal of Clinical Oncology · 被引 3)
• RC48G001: A phase 2 study of disitamab vedotin in HER2-expressing previously treated advanced UC. (2026 · Journal of Clinical Oncology · 被引 2)
• Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial (2026 · The Lancet · 被引 1)
• Initial results from EXCEED, a phase 1 study of LY4101174, an antibody-drug conjugate targeting Nectin-4, in participants with advanced or metastatic urothelial carcinoma. (2026 · Journal of Clinical Oncology · 被引 1)
• Efficacy and Safety of Investigational Treatments in Contemporary Early-Phase Clinical Trials for Japanese Gynecologic Cancers: A Single-Institution Retrospective Analysis (2026 · JCO oncology advances.)